D1 dopamine receptor activity of anti-Parkinsonian drugs

Life Sciences

Volumn 60, Issue 18, 1997, Pages 1597-1603

  Fici, G J ^a   Wu, H ^a   VonVoigtlander, P F ^a   Sethy, Vimala H ^a  

^a PFIZER INC   (United States)

Author keywords

D1 dopamine receptors; dopamine agonists; dyskinesias; Parkinson's disease; primary cerebellar granule cell cultures

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PRAMIPEXOLE; U 95666A; UNCLASSIFIED DRUG; 7 HYDROXY 2 N,N DIPROPYLAMINOTETRALIN; 7-HYDROXY-2-N,N-DIPROPYLAMINOTETRALIN; BENZOTHIAZOLE DERIVATIVE; PRAMIPEXOL; TETRALIN DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DYSKINESIA; GRANULE CELL; NERVE CELL CULTURE; NEWBORN; NONHUMAN; PARKINSON DISEASE; RAT; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BENZOTHIAZOLES; BROMOCRIPTINE; CELLS, CULTURED; CEREBELLUM; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; PERGOLIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; TETRAHYDRONAPHTHALENES; THIAZOLES;

EID: 0030611063     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00126-4     Document Type: Article

References (20)

1. C.D. MARSDEN and J.D. PARKES, Lancet 1 345-349 (1977).
2. J.P. BENNETT, Jr., E.R. LANDOW and L.A. SCHUH, Neurology 43 1551-1555 (1991).
3. T.J. PARRY, K. EBERLE-WANG, I. LUCKI and M.-F. CHESSELET, Exp. Neurol. 128 181-190 (1994).
4. K.K. GNANALINGHAM, D.D. EROL, A.J. HUNTER, L.A. SMITH, P. JENNER and C.D. MARSDEN, Psychopharmacology 117 275-286 (1995).
5. Y. IKAI, M. TAKADA, Y. SHINONAGA and N. MIZUNO, Neuroscience 51 719-728 (1992).
6. T.M. DAWSON, P. BARONE, A. SIDHU, J.K. WAMSLEY and T.N. CHASE, Neuroscience 26 83-100 (1988).
7. A. NOVELLI, J.A. REILLY, P.G. LYSKO and R.C. HENNEBERRY, Brain Res. 452 105-112 (1988).
8. f. NICOLETTI, J.T. WROBLEWSKI, A. NOVELLI, H. ALHO, A GUIDOTTI and E. COSTA, J. Neurosci. 6 1905-1911 (1986).
9. A.J. LEES and G.M. STERN, J. Neurol. Neurosurg. Psychiat. 44 1020-1023 (1981).
10. P.J. BEDARD, T. DiPAOLO, P. FALARDEAU and R. BOUCHER, Brain Res. 379 294-299 (1986).
11. A.N. LIEBERMAN, M. GOLDSTEIN, M. LEIBOWITZ, G. GOPINATHAM, A. NEOPHYTIDE, E. HIESIGER, J. NELSON R. WALKER, Neurology 34 223-226 (1984).
12. F. BARONTI, M. MOURADIAN, T.L. DAVIS, M. GUIFFRA, G. BRUGHITTA, K.E. CONANT and T.N. CHASE, Ann. Neurol. 32 776-781 (1992).
13. S.T. GANCHER, W.R. WOODARD, B. BOUCHER and J.G. NUTT, Ann. Neurol. 26 232-238 (1989).
14. M.M. MOURADIAN, I.J.E. HEUSER, F. BARONTI, M. GIUFFRA, K. CONANT, T.L. DAVIS and T.N. CHASE, J. Neurol. Neurosurg. Psychiat. 54 401-405 (1991).
15. V.H. SETHY, B.R. ELLERBROCK and H. WU, Neurosci. Abstr. 21 1254 (1995).
16. V.H. SETHY, B.R. ELLERBROCK, G.J. FICI and H. WU, Brain Res., 733 41-45 (1996).
17. D. Clark and F.J. White, Synapse 1 347-388 (1987).
18. H.E. CRISWELL, R.A. MUELLER and G.A. BREESE, Eur. J. Pharmacol. 159 141-147 (1989).
19. A.V. CHRISTENSEN, J. ARNT, J. HYTTEL, J.-J. LARSEN and O. SVENDSEN, Life Sci. 34 1529-1540 (1984).
20. H.Y. MELTZER, S. MATSUBARA and J.C. LEE, J.. Pharmacol. Exp. Ther. 251 238-246 (1989).